Shaanxi Micot Pharmaceutical Technology's (HKG:2335) research results for XTL6001 have been accepted for presentation at multiple academic conferences in the fields of diabetes, metabolic diseases, and nephrology.
Following an initial presentation at the American Diabetes Association, additional analysis will be presented at the upcoming European Association for the Study of Diabetes (EASD) and American Society of Nephrology (ASN) annual meetings, according to a Monday Hong Kong bourse filing.
Two research abstracts will be featured at the 62nd annual meeting of the EASD, with one to be presented at ASN Kidney Week 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments